This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co, Inc.
Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma
Daniel M. Siegel, MD, MS, FAAD, FACMS
SUNY Downstate Medical Center, Department of Dermatology
Brianna Hoffner, MS, ANP-BC,AOCNP®
Univ of Colorado Cancer Center
Novel, cutting-edge therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique, potentially severe or even lethal immune-related adverse events (irAEs). Many advanced practitioners lack familiarity with newer immunotherapies and hedgehog inhibitors. This learning activity will equip APs with the knowledge needed to provide safe, state-of-the-art care for their patients with melanoma or basal cell skin cancer.
These CME/CE/CPE accredited activities are jointly provided by